University of Maryland brings relief for bowel disease sufferers
BALTIMORE — The University of Maryland Ventures and Biomecite Diagnostics are at work on developing an innovative diagnostic test for inflammatory bowel disease.
The technology explores distinctive genomic variances in the populations of bacteria or microbiome found in the human gut to diagnose the closely related but differing gastrointestinal diseases, UC and CD.
Current methods for the clinical diagnosis of UC and CD, as well as between IBD and other gastrointestinal diseases, remain very challenging because health care providers must subjectively interpret clinical symptoms and because of the invasive nature of procedures such as endoscopies and colonoscopies. The UMB technology, however, relies on the analysis of signature genetic sequences obtained directly from the stool samples of patients. This state-of-the-art technology belongs to the rapidly expanding field of microbiome-based diagnostics, fueled by the development of increasingly efficient and cost-effective DNA-sequencing technologies.
“Biomecite Diagnostics is a particularly exciting UMB startup. Its next-generation, microbiome-based technology for diagnosing inflammatory bowel diseases has the potential to provide a non-invasive and more cost effective alternative to currently used diagnostic procedures,” said Phil Robilotto, chief commercialization officer, UM Ventures, Baltimore. “Biomecite has built a very strong scientific and management team with a well-established track record, and has already made significant progress on the development of relationships with several key partners to enable technology commercialization.”
Source: PR Newswire